Literature DB >> 27831571

Diabetes: Incretin mimetics and insulin - closing the gap to normoglycaemia.

Michael A Nauck1, Juris J Meier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27831571     DOI： 10.1038/nrendo.2016.180

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Authors:  John B Buse; Richard M Bergenstal; Leonard C Glass; Cory R Heilmann; Michelle S Lewis; Anita Y M Kwan; Byron J Hoogwerf; Julio Rosenstock
Journal:  Ann Intern Med       Date:  2010-12-06       Impact factor: 25.391

2.  Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis.

Authors:  M A Abdul-Ghani; K Williams; M Kanat; Y Altuntas; R A DeFronzo
Journal:  J Endocrinol Invest       Date:  2012-04-18       Impact factor: 4.256

3.  Is insulin the most effective injectable antihyperglycaemic therapy?

Authors:  J B Buse; A Peters; D Russell-Jones; S Furber; M Donsmark; J Han; L MacConell; D Maggs; M Diamant
Journal:  Diabetes Obes Metab       Date:  2014-11-09       Impact factor: 6.577

4.  Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Authors:  Julio Rosenstock; Ronnie Aronson; George Grunberger; Markolf Hanefeld; PierMarco Piatti; Pierre Serusclat; Xi Cheng; Tianyue Zhou; Elisabeth Niemoeller; Elisabeth Souhami; Melanie Davies
Journal:  Diabetes Care       Date:  2016-08-15       Impact factor: 19.112

5.  Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.

Authors:  Olga Montvida; Kerenaftali Klein; Sudhesh Kumar; Kamlesh Khunti; Sanjoy K Paul
Journal:  Diabetes Obes Metab       Date:  2016-10-18       Impact factor: 6.577

6.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

7.  Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Authors:  Stephen C L Gough; Bruce Bode; Vincent Woo; Helena W Rodbard; Sultan Linjawi; Pernille Poulsen; Lars H Damgaard; John B Buse
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09-01       Impact factor: 32.069

Review 8.  Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.

Authors:  Conrad Eng; Caroline K Kramer; Bernard Zinman; Ravi Retnakaran
Journal:  Lancet       Date:  2014-09-11       Impact factor: 79.321

Review 9.  Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.

Authors:  R Balena; I E Hensley; S Miller; A H Barnett
Journal:  Diabetes Obes Metab       Date:  2012-11-12       Impact factor: 6.577

10.  Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

Authors:  J Hans DeVries; Stephen C Bain; Helena W Rodbard; Jochen Seufert; David D'Alessio; Anne B Thomsen; Marcin Zychma; Julio Rosenstock
Journal:  Diabetes Care       Date:  2012-05-14       Impact factor: 19.112
  10 in total
  1 in total

1.  Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high-fat diet.

Authors:  Noriyuki Kaji; Yoshiichi Takagi; Satomi Matsuda; Anna Takahashi; Sakurako Fujio; Fumitoshi Asai
Journal:  Animal Model Exp Med       Date:  2020-03-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.